Table 3.
Characteristics of patient bone metastases.
| Bone Metastasis Hormonal Status | N (%)* | Receptor Discordanceǂ | De Novo | Other Metastatic Sites | Received Bone-Targeted Therapy | Received Surgery |
|---|---|---|---|---|---|---|
| ER+/HER2− | 57/80 (71.3%) | 12/57 (21%) | 15/57 (26.3%) | 50/57 (87.7%) | 53/57 (98.1%) | 35/57 (61.4%) |
| ER+/HER2+ | 10/80 (12.5%) | 2/10 (20%) | 1/10 (10%) | 9/10 (90%) | 9/10 (90%) | 4/10 (40%) |
| ER-/HER2+ | 2/80 (2.5%) | 2/2 (100%) | 1/2 (50%) | 1/2 (50%) | 2/2 (100%) | 0/2 (0%) |
| ER-/HER2− | 11/80 (13.7%) | 5/11 (45.5%) | 0/11 (0%) | 9/11 (81.8%) | 7/11 (63.6%) | 2/11 (18.2%) |
*Total number of patients (n=80) that receptor status was documented in clinical records for ER, PR, and HER2 for both primary tumors and bone metastases.
ǂRecorded if any of the receptors (ER, PR, HER2) switched from what was reported for the primary tumor.